JAKAVI 10 MG COMPRIMIDOS 에콰도르 - 스페인어 - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

jakavi 10 mg comprimidos

novartis pharma a.g. suiza - ruxolitinib----10.00 mg - comprimidos - cada comprimido contiene: fosfato de ruxolitinib----13.20 mg equivalente a ruxolitinib----10.00 mg

JAKAVI 5 mg Comprimidos 에콰도르 - 스페인어 - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

jakavi 5 mg comprimidos

novartis pharma a.g. [ch] switzerland - ruxolitinib----5.00 mg - comprimidos - cada comprimido contiene: fosfato de ruxolitinib cas 941678-49-5----6.60 mg equivalente a ruxolitinib----5.00 mg

JAKAVI 15 mg Comprimidos 에콰도르 - 스페인어 - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

jakavi 15 mg comprimidos

novartis pharma a.g. [ch] switzerland - ruxolitinib----15.000 mg - comprimidos - cada comprimido contiene: fosfato de ruxolitinib cas 941678-49-5----19.80 mg equivalente a ruxolitinib----15.00 mg

JAKAVI 20mg COMPRIMIDOS 에콰도르 - 스페인어 - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

jakavi 20mg comprimidos

novartis pharma a.g. [ch] switzerland - ruxolitinib----20.00 mg - comprimidos - cada comprimido contiene: fosfato de ruxolitinib cas 941678-49-5----26.40 mg equivalente a ruxolitinib----20.00 mg

Inrebic 유럽 연합 - 스페인어 - EMA (European Medicines Agency)

inrebic

bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - agentes antineoplásicos - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.